Register
Federal court issues decision holding that US Stem Cell clinics and owner adulterated and misbranded stem cell products |
Clinical News
eMediNexus Coverage from: 
Federal court issues decision holding that US Stem Cell clinics and owner adulterated and misbranded stem cell products
eMediNexus,  06 June 2019
remove_red_eye 522 Views
#Business And Medicine #Internal Medicine #Pharmacist #Public Health

0 Read Comments                

U.S. District Judge Ursula Ungaro of the Southern District of Florida granted the government’s motion for summary judgment against US Stem Cell Clinic LLC, of Weston, Florida, and US Stem Cell Inc., of Sunrise, Florida, and their Chief Scientific Officer Kristin Comella, Ph.D. The court held that the defendants in that case adulterated and misbranded a stem cell drug product made from a patient’s adipose tissue.

“Cell-based regenerative medicine holds significant medical opportunity, but those in this field who do not operate in compliance with the law can potentially cause serious harm to patients,” said Acting FDA Commissioner Ned Sharpless, M.D. (FDA, June 4, 2019)

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now